Daily aspirin may slash liver cancer risk in cirrhosis patients
NCT ID NCT07529262
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking a low-dose aspirin (100 mg) every day can prevent liver cancer in people with cirrhosis, a condition that raises cancer risk. About 890 adults from Australian hospitals will take aspirin or a placebo for 4 years while continuing their regular check-ups. If successful, aspirin could become a simple, low-cost way to protect against liver cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- A new procedure may offer relief for Cirrhosis-Related fluid buildup
- Can liver damage predict how drugs behave?
- Better crystal ball for liver crisis: new scores put to the test
- Blood thinner may stop early cirrhosis from turning deadly — a major trial puts it to the test
- Stick-On ultrasound patch could spot liver damage without a specialist